Preoperative Oral Pregabalin Effect on Inhalational Anesthetic Requirements ln Hysterectomy Under General Anesthesia

Model scores of the 29,894 trials active now.

Model score 7% for any early termination, 4% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 14% of the time (741 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2017-09-20. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (lowers risk) · Wording Phrases that raised it: pregabalincontrolledeffective in18reducing
  Phrases that lowered it: anesthesiageneralelectiveasaamerican
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Phase: 3 (lowers risk) · Design
• Drug's FAERS reports marked serious: 59.8% (lowers risk) · Drug's FDA history
• Primary purpose: health services research (lowers risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 5.7% (lowers risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Responsible party: sponsor investigator (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Design: parallel (raises risk) · Design
• Maximum age: 60 (lowers risk) · Who can join
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Number of arms: 2 (raises risk) · Design
• Sponsor's past trials: 0 (lowers risk) · Sponsor's track record
• Blinding: double (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Pregabalin in the Prevention of Postoperative Delirium and Pain NCT00819988 · started 2009 · scored riskier than 15% of active trials completed
• Perioperative Pregabalin for Reducing Opioid Consumption After Cardiac Surgery NCT04517110 · started 2021 · scored riskier than 27% of active trials terminated
• Preemptive Oral Gabapentin 600 mg in Reducing Morphine Requirement After Non Obstetric Lower Abdominal Surgery NCT04434430 · started 2019 · scored riskier than 7% of active trials completed
• Analgesic Potentials of Preoperative Pregabalin,Magnesium Sulphate and Their Combination in Acute Post-thoracotomy Pain NCT02678117 · started 2015 · scored riskier than 7% of active trials completed
• Study To Investigate The Effectiveness Of Pregabalin For Management Of Patients Undergoing Total Hip Replacement NCT00905437 · started 2009 · scored riskier than 34% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.